• Telix recorded an operating profit of $49.9 million, up 858% from 2023
• Total revenue grew 56% to $783.2 million, driven by strong U.S. sales of Illuccix®
• R&D expenditure increased to $194.6 million to support pipeline development

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) has announced its financial results for the year ended 31 December 2024. The company recorded an operating profit of $49.9 million, up 858% from $5.2 million in the previous year. Total revenue grew 56% to $783.2 million, primarily driven by continued strong growth in U.S. sales of Illuccix®, Telix's lead imaging product. Operating expenditure for the year totaled $727.2 million, including $194.6 million related to R&D activities for the company's assets and development programs. Income tax expense for the year was $6.1 million. Telix's Annual General Meeting will be held on 21 May 2025, with the closing date for director nominations set for 9 April 2025. The company remains focused on the development and commercialization of its theranostic pipeline, which spans urologic oncology, neuro-oncology, musculoskeletal oncology, and hematologic oncology. Telix continues to expand its global footprint, with operations in 29 countries and recent acquisitions and in-licensing deals to strengthen its platform and pipeline.

Telix expects continued strong growth in revenue and profitability in the 2025 financial year, driven by further expansion of Illuccix® sales in the U.S. and international markets.

Telix remains focused on advancing its theranostic pipeline, with key milestones expected in 2025 including the completion of the Phase 3 ProstACT GLOBAL trial for its prostate cancer therapeutic and the continued global expansion of Illuccix®. The company is also actively pursuing additional strategic acquisitions and in-licensing opportunities to further strengthen its position as a leader in precision oncology.